Dermatology · Woodbury, NY
NPI
1699749713
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
160 Crossways Park Dr
Woodbury, NY, 11797
Phone (516) 364-4200
Groups this clinician bills Medicare through
Medicare paid, 2024
$304K
5,172 services
Medicare patients, 2024
890
Average age 74
Drug cost, 2024
$237K
1,010 prescriptions
Company payments, 2025
$7,413
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eve Lupenko was code 17003 (destruction skin lesion), 1,660 times for 231 patients. In total Eve Lupenko billed 5,172 services in 28 codes, and Medicare paid $304K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,660 | 231 | $6.15 | $10K |
| 99213 Office E&M - Established | Office | 1,413 | 713 | $78.61 | $111K |
| 17110 Destruction Skin Lesion | Office | 525 | 330 | $105.60 | $55K |
| 17000 Destruction Skin Lesion | Office | 458 | 295 | $46.99 | $22K |
| 11102 Skin Biopsy | Office | 305 | 244 | $83.78 | $26K |
| 17004 Destruction Skin Lesion | Office | 213 | 108 | $156.44 | $33K |
| 99203 Office E&M - New | Office | 127 | 127 | $90.72 | $12K |
| 99214 Office E&M - Established | Office | 93 | 78 | $114.25 | $11K |
| 17111 Destruction Skin Lesion | Office | 89 | 61 | $126.39 | $11K |
| 11103 Skin Biopsy | Office | 82 | 60 | $49.85 | $4,088 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 68 | 33 | $0.72 | $49.06 |
| 11900 Skin | Office | 67 | 33 | $45.24 | $3,031 |
| 99212 Office E&M - Established | Office | 19 | 16 | $47.20 | $897 |
| 99204 Office E&M - New | Office | 14 | 14 | $141.51 | $1,981 |
By year: 2022 $295K for 4,365 services; 2023 $323K for 5,436 services; 2024 $304K for 5,172 services.
Medicare prescription drug claims, 2024
In 2024, the drug Eve Lupenko prescribed most often to Medicare patients was Mupirocin, with 108 prescriptions and refills. In total Eve Lupenko wrote 1,010 Medicare prescriptions that cost $237K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mupirocin Generic | 108 | 108 | 82 | $726 |
| Hydrocortisone Generic | 106 | 108 | 87 | $518 |
| Triamcinolone Acetonide Generic | 86 | 88 | 73 | $739 |
| Clobetasol Propionate Generic | 74 | 86 | 47 | $4,221 |
| Clindamycin Phosphate Generic | 56 | 56 | 43 | $3,368 |
| Fluocinonide Generic | 55 | 57 | 38 | $2,719 |
| Azelaic Acid Generic | 53 | 56 | 27 | $7,499 |
| Doxycycline Hyclate Generic | 48 | 52 | 41 | $368 |
| Ciclopirox Ciclopirox Olamine | 47 | 54 | 33 | $900 |
| Metronidazole Generic | 30 | 38 | 22 | $1,867 |
| Ketoconazole Generic | 21 | 21 | Under 11 | $812 |
| Ciclopirox Generic | 21 | 21 | 13 | $555 |
| Klisyri Tirbanibulin | 20 | 20 | 14 | $23K |
| Valacyclovir Valacyclovir Hcl | 19 | 19 | 11 | $264 |
| Gentamicin Sulfate Generic | 19 | 19 | 14 | $833 |
Brand drugs: 119 claims; generic drugs: 891 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eve Lupenko $7,413 ($7,413 in general payments such as food, travel and fees) from 21 companies. The largest payer was Journey Medical Corporation with $3,147.
| Company | Payments | Amount |
|---|---|---|
| Journey Medical Corporation DERM | 4 | $3,147 |
| Arcutis Biotherapeutics, Inc. ARQT | 23 | $1,200 |
| Incyte Corporation INCY | 17 | $585 |
| Janssen Biotech, Inc. JNJ | 13 | $500 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 17 | $365 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $311 |
| UCB, Inc. UCB.BR | 10 | $279 |
| Pfizer Inc. PFE | 10 | $263 |
| Galderma Laboratories, L.P. GALD.SW | 16 | $260 |
| Abbvie Inc. ABBV | 9 | $139 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.